Trial Profile

A Phase II Clinical Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 18 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amcasertib (Primary)
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Biomarker; Therapeutic Use
Sponsors Sumitomo Pharma America; Sumitomo Pharma Oncology

Most Recent Events

03 Aug 2022 According to ClinicalTrials.gov record, protocol has been amended to change in timeframe for primary end point from 8 weeks to 8-24 weeks.
25 Mar 2019 Status changed from active, no longer recruiting to discontinued.
10 Sep 2018 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com